Drugs / BAY1128688
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02434640 | Apr → Dec 2015 | endometriosis | Bayer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03373422 | Nov 2017 → Jul 2018 | endometriosis | Bayer | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY1128688 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02434640 ↗ |
| Action | Inhibit | “BAY1128688 is a selective inhibitor of aldo-keto reductase family 1 member C3 (AKR1C3)” PMID 37422772 ↗ Jul 2023 |
| Route | Oral | “Different Oral Doses of BAY1128688 in Women With Symptomatic Endometriosis Over a 12-week Treatment Period” NCT03373422 ↗ |
| Target | AKR1C3 | “Here, we analyzed pharmacodynamic data from a phase 1 study with a new selective AKR1C3 inhibitor, BAY1128688, to identify response biomarkers and assess effects on ovarian function.” PMID 37306288 ↗ Jul 2023 |